Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of gram-negative pathogens

被引:11
作者
Bhavnani, SM
Hammel, JP
Forrest, A
Jones, RN
Ambrose, PG
机构
[1] Cognigen Corp, Buffalo, NY 14221 USA
[2] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY USA
[3] Jones Grp, JMI Labs, N Liberty, IA USA
[4] Tufts Univ, Sch Med, Boston, MA 02111 USA
[5] Univ Pacific, Sch Hlth Sci, Stockton, CA 95211 USA
关键词
D O I
10.1086/375817
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The identification of patients infected with antibiotic-resistant strains of bacteria for inclusion in clinical trials remains a serious challenge for the future development of agents for use against such infections. To identify patient- and institution-specific factors predictive of reduced susceptibility of Enterobacter species, Pseudomonas aeruginosa, and Klebsiella pneumoniae to cefepime, ciprofloxacin, and piperacillin-tazobactam, 5 years (1997 - 2001) of North American surveillance data were analyzed. The relationship between minimum inhibitory concentration ( MIC) values for each organism-agent pair and patient- and institution-specific variables was analyzed using multivariable general linear modeling. The variables most commonly associated with decreases in susceptibility were duration of hospital stay before pathogen isolation, hospital size, primary diagnosis, and medical service. Combinations of these variables were associated with increases in observed MIC 90 values of as much as 16-32-fold. Our findings demonstrate a relationship between MIC and certain patient- and institution-specific variables. Such data should be considered in the design of clinical trials directed at the study of resistant pathogens.
引用
收藏
页码:344 / 350
页数:7
相关论文
共 11 条
[1]   Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. [J].
Davidson, R ;
Cavalcanti, R ;
Brunton, JL ;
Bast, DJ ;
de Azavedo, JCS ;
Kibsey, P ;
Fleming, C ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) :747-750
[2]   Is there hope for the prevention of future antimicrobial shortages? [J].
Gilbert, DN ;
Edwards, JE .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (02) :215-216
[3]   Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E-faecium [J].
Linden, PK ;
Pasculle, AW ;
Manez, R ;
Kramer, DJ ;
Fung, JJ ;
Pinna, AD ;
Kusne, S .
CLINICAL INFECTIOUS DISEASES, 1996, 22 (04) :663-670
[4]   Does antimicrobial resistance cluster in individual hospitals? [J].
McGowan, JE ;
Hill, HA ;
Volkova, NV ;
Lawton, RM ;
Haber, MJ ;
Tenover, FC ;
Gaynes, RP .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (09) :1362-1365
[5]  
*NCCLS, 2003, M100S13 NCCLS
[6]  
NCCLS, 2003, M7A6 NCCLS
[7]   Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases:: Implications for the clinical microbiology laboratory [J].
Paterson, DL ;
Ko, WC ;
Von Gottberg, A ;
Casellas, JM ;
Mulazimoglu, L ;
Klugman, KP ;
Bonomo, RA ;
Rice, LB ;
McCormack, JG ;
Yu, VL .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (06) :2206-2212
[8]   Methods for data mining from large multinational surveillance studies [J].
Poupard, J ;
Brown, J ;
Gagnon, R ;
Stanhope, MJ ;
Stewart, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2409-2419
[9]   Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species [J].
Sanders, WE ;
Tenney, JH ;
Kessler, RE .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) :454-461
[10]   Is there hope for the prevention of future antimicrobial shortages? Reply [J].
Shlaes, DM .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (02) :216-217